Certara, Inc. (CERT)

NASDAQ: CERT · IEX Real-Time Price · USD
17.72
+0.25 (1.43%)
Dec 5, 2022 4:00 PM EST - Market closed
1.43%
Market Cap 2.79B
Revenue (ttm) 324.36M
Net Income (ttm) -4.14M
Shares Out 157.14M
EPS (ttm) -0.09
PE Ratio n/a
Forward PE 32.89
Dividend n/a
Ex-Dividend Date n/a
Volume 781,673
Open 17.35
Previous Close 17.47
Day's Range 17.31 - 17.82
52-Week Range 10.6 - 29.99
Beta n/a
Analysts Buy
Price Target 20.97 (+18.3%)
Earnings Date Nov 7, 2022

About CERT

Certara, Inc. provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development. The company also provides related technology-enabled services to guide its customers' new drugs through the regulatory submission process and into the market. Its technology-enabled services include mechanistic biosim... [Read more]

Industry Health Information Services
IPO Date Dec 11, 2020
Employees 1,054
Stock Exchange NASDAQ
Ticker Symbol CERT
Full Company Profile

Financial Performance

In 2021, Certara's revenue was $286.10 million, an increase of 17.48% compared to the previous year's $243.53 million. Losses were -$13.27 million, -73.14% less than in 2020.

Financial Statements

Analyst Forecast

According to 15 analysts, the average rating for CERT stock is "Buy." The 12-month stock price forecast is 20.97, which is an increase of 18.34% from the latest price.

Price Target
$20.97
(18.34% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Why Certara's Shares Rose 37.7% This Week

The company, which helps other companies in their drug development, reported strong third-quarter numbers.

3 weeks ago - The Motley Fool

Certara, Inc. (CERT) Q3 Earnings Miss Estimates

Certara, Inc. (CERT) delivered earnings and revenue surprises of -9.09% and 2.84%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

3 weeks ago - Zacks Investment Research

Certara Reports Third Quarter 2022 Financial Results

Biosimulation software and services fuel third quarter growth Biosimulation software and services fuel third quarter growth

4 weeks ago - GlobeNewsWire

Arsenal Capital Partners Increases Investment in Global Biosimulation Leader Certara with $449M Stock Purchase

Arsenal will acquire approximately 30M shares at $15 per share from funds controlled by EQT Private Equity and agrees to two-year lock-up on sale of shares Arsenal will acquire approximately 30M shares ...

4 weeks ago - GlobeNewsWire

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor conf...

1 month ago - GlobeNewsWire

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) Renews Licenses of Certara's Software for Evaluating Regula...

The PMDA enters 9th consecutive year of using Certara's software The PMDA enters 9th consecutive year of using Certara's software

1 month ago - GlobeNewsWire

Certara to Report Third Quarter 2022 Financial Results on November 7th, 2022

PRINCETON, N.J., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2022 af...

1 month ago - GlobeNewsWire

Here's Why Certara Stock Is Falling Friday

Certara Inc (NASDAQ: CERT) shares are trading lower by 15.40% to $17.08 Friday morning after the company announced a secondary offering of 7 million shares of common stock. What Else?

3 months ago - Benzinga

Certara Announces Secondary Offering

PRINCETON, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) (“Certara”), a global leader in biosimulation, today announced the sale by certain stockholders (the “Selling Stockholders...

3 months ago - GlobeNewsWire

Certara, Inc. (CERT) Q2 Earnings and Revenues Miss Estimates

Certara, Inc. (CERT) delivered earnings and revenue surprises of -18.18% and 3.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Certara Reports Second Quarter 2022 Financial Results

Biosimulation software and services fuel second quarter growth Biosimulation software and services fuel second quarter growth

3 months ago - GlobeNewsWire

Certara Introduces Update of Pinnacle 21™ Enterprise and New Pinnacle 21™ Data Exchange Module

New automation, analytics and collaboration features save time and ensure regulatory compliance New automation, analytics and collaboration features save time and ensure regulatory compliance

4 months ago - GlobeNewsWire

Certara Announces Collaboration with Leading Cancer Center to Advance CAR T-cell Therapies

Certara and Memorial Sloan Kettering Cancer Center to develop biosimulation platform for CAR T-cell therapies Certara and Memorial Sloan Kettering Cancer Center to develop biosimulation platform for CAR...

4 months ago - GlobeNewsWire

Certara Appoints Rosemary Crane as New Independent Board Member

PRINCETON, N.J., July 25, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Rosemary Crane to its Board of Directors, effective ...

4 months ago - GlobeNewsWire

Certara Appoints Eran Broshy as New Independent Board Member

PRINCETON, N.J., July 13, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the appointment of Eran Broshy to its Board of Directors, effective Jul...

4 months ago - GlobeNewsWire

Certara to Report Second Quarter 2022 Financial Results on August 9th, 2022

PRINCETON, N.J., July 12, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of 2022 a...

4 months ago - GlobeNewsWire

Certara Introduces New Simcyp™ Discovery Simulator for Early-Stage and Translational Drug Development

Advances lead optimization, first-in-human dose prediction and formulation development Advances lead optimization, first-in-human dose prediction and formulation development

5 months ago - GlobeNewsWire

Certara Announces New Versions of Biosimulation Software for Development of Novel Biologics

New capabilities enhance clinical predictability for different compounds across more therapeutic areas New capabilities enhance clinical predictability for different compounds across more therapeutic areas

5 months ago - GlobeNewsWire

Certara, Inc. (CERT) Matches Q1 Earnings Estimates

Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 2.22%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Certara Reports First Quarter 2022 Financial Results

PRINCETON, N.J., May 05, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the first quarter of fiscal year 2022.

7 months ago - GlobeNewsWire

Certara to Report First Quarter 2022 Financial Results on May 5th, 2022

PRINCETON, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2022 a...

7 months ago - GlobeNewsWire

Certara, Inc. (CERT) Soars 6.1%: Is Further Upside Left in the Stock?

Certara, Inc. (CERT) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase...

8 months ago - Zacks Investment Research

Why Certara Shares Are Plunging Today

Certara Inc's (NASDAQ: CERT) Q4 FY21 sales increased 17% to $75.3 million, missing the consensus of $83.26 million. The increase was driven by $6.1 million in revenue from Pinnacle 21, acquired in Q4 f ...

9 months ago - Benzinga

Certara, Inc. (CERT) Q4 Earnings and Revenues Lag Estimates

Certara, Inc. (CERT) delivered earnings and revenue surprises of -88.89% and 8.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Certara Reports Fourth Quarter and Full Year 2021 Financial Results

PRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2021 and ...

9 months ago - GlobeNewsWire